Maxim Group analyst Allen Klee reiterated a Buy rating on Augmedix (AUGX – Research Report) yesterday and set a price target of $8.00. The company’s shares closed yesterday at $3.37.
Klee covers the Technology sector, focusing on stocks such as Interlink Electronics, Marpai, and CareCloud. According to TipRanks, Klee has an average return of -21.3% and a 23.30% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Augmedix with a $6.50 average price target, implying a 92.88% upside from current levels. In a report released yesterday, B.Riley Financial also reiterated a Buy rating on the stock with a $5.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.29 and a one-year low of $1.01. Currently, Augmedix has an average volume of 1.12M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Augmedix Inc humanizes the clinician-patient experience by enabling clinicians to focus on what matters most, delivering high-quality patient care. It converts natural clinician-patient conversation into medical documentation and provides real-time administrative support, including referrals, orders, and reminders. The service, which supports over 35 specialties, delivers timely, accurate and comprehensive medical documentation to several of the healthcare systems in the U.S. and to hundreds of independent clinicians nationwide. Augmedix focuses on saving clinicians 2-3 hours per day, improve clinician productivity by as much as 20%, and increase clinicians’ satisfaction with work-life balance over 40%.
Read More on AUGX:
